Selecting a CRO without a tender. What is a direct CRO selection and how can it be justified?
Selecting a CRO “without a tender” (direct selection) means entrusting the execution of a clinical trial to a specific Contract Research Organization without conducting a formal competitive procedure, such as a tender, Request for Proposal (RFP), call for bids, or comparison of multiple price offers. Such a decision is usually based on previous cooperation, proven experience of the CRO, or unique competencies that are crucial for the specific project.
In practice, direct CRO selection is used in situations where time is critical, the study is highly complex, or specialized know-how is required that is not widely available on the market. This may include studies involving an innovative Investigational Medicinal Product (IMP), trials conducted in narrow patient populations, projects requiring advanced regulatory support, or Investigator Initiated Studies.
This model of CRO selection does not mean a lack of control or reduced standards. On the contrary, a direct selection decision should be well considered and justified. It should be based on an analysis of competencies, operational resources, team availability, and experience in similar projects. In many organizations, such a decision requires formal business or regulatory justification explaining why a particular CRO is the best fit for the project.
One of the main advantages of selecting a CRO without a tender is the reduction of the study start-up timeline. Avoiding lengthy bidding processes allows sponsors to move quickly to the operational planning phase. Additionally, cooperation with a previously verified partner reduces the risk of misunderstandings, communication issues, and different interpretations of responsibilities.
On the other hand, the lack of a competitive procedure requires particularly careful definition of the scope of services, budget, and key performance indicators (KPIs) in order to ensure transparency and full cost control. Trust in the CRO and its ability to report progress and risks in a transparent manner also become essential.
From a strategic perspective, direct CRO selection works best in projects where quality, experience, and predictability of execution are more important than comparing multiple price offers. A well-chosen CRO partner in such a model can significantly accelerate the project, reduce operational risks, and ensure stable execution even for the most demanding clinical trials.
If you are considering selecting a CRO without a tender and want to ensure that this decision translates into efficient and secure study execution, contact us. We will be happy to show how we support projects that require a trusted and experienced CRO partner.
